Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Wins in Vegas!

  • Major interest generated in Lexaria’s technology at MJBizCon
  • Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect
  • Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience

This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand for improved edible products in the market, with dispensary owners showing a refreshingly new willingness to carry CBD-based edibles on their shelves and manufacturers displaying a keen interest in Lexaria’s patented DehydraTECH™ delivery technology to incorporate in their products. To accommodate all of the interest shown, as well as requests for business discussions, the company intends to expand its sales team and infrastructure.

Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids, including CBD, as well as for the delivery of THC and other psychoactive cannabinoids. This delivery technology masks the taste of edibles, eliminating the need for unhealthy sugars and sweeteners used in many products to mask bitter flavors. It also increases bio-absorption of cannabinoids and other active compounds by up to 10 times and reduces the time of onset of effects, which were previously typically 60 to 120 minutes, to between 15 and 20 minutes. These capabilities are in marked contrast to other technologies through which active compounds are bad tasting upon oral intake, broken down by the liver, largely destroyed by stomach acid and unable to cross the intestinal wall to any significant degree.

In August 2015, Lexaria initiated an in vitro study which showed an increase of up to 499 percent in CBD bioabsorption in human intestinal tissues using its technology. In February 2017, Lexaria signed a collaboration agreement with Canada’s National Research Council to investigate the bioavailability enhancement of lipophilic active ingredients and to determine the best methods for processing these active compounds within foods. The company’s patents include a wide range of lipophilic active compounds that can be formulated and delivered using the company’s technology, including cannabinoids, vitamins, NSAIDs and nicotine. They also cover numerous product dosage forms, including foods, liquids, emulsions, tablets and capsules.

Lexaria prides itself on being a technology disruptor in the rapidly emerging cannabis market. For manufacturers, it reduces the cannabinoid per serving unit cost, or it can deliver stronger effects in environments where serving levels are regulated. Consumers benefit greatly from the better taste of edibles and the reduced time to effect. Lexaria has developed several CBD-based products for demonstration, testing and sales, including protein energy bars, CBD tablets, exotic teas and TurboCBD™ high absorption hemp oil capsules. To date, the company has signed royalty agreements with several companies in the United States and Canada.

Overall, Lexaria’s technology enables the lowest cost per serving and best consumer experience, which are major benefits for manufacturers of edibles in an increasingly competitive market. Judging by the level of interest in Lexaria’s patented technology generated at MJBizCon, the company is headed for a very bright future.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Archives

Select A Month

Contact us: 303.498.7722